[et_pb_section fb_built=”1″ _builder_version=”4.21.0″ custom_margin=”180px||||false|false” global_colors_info=”{}”][et_pb_row _builder_version=”4.27.5″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” max_width=”none” global_colors_info=”{}”][et_pb_column type=”4_4″ _builder_version=”4.16″ custom_padding=”|||” global_colors_info=”{}” custom_padding__hover=”|||”][et_pb_text admin_label=”UNITE4TB” _builder_version=”4.21.0″ background_size=”initial” background_position=”top_left” background_repeat=”repeat” global_colors_info=”{}”]<\/p>\n
[\/et_pb_text][et_pb_text _builder_version=”4.27.5″ _module_preset=”default” hover_enabled=”0″ global_colors_info=”{}” sticky_enabled=”0″]<\/p>\n
Seven year \u20ac185 million project.\u00a0 Thirty partners from 13 countries to deliver an efficient global clinical trials network equipped to implement phase 2 trials that conform to the highest regulatory standards.\u00a0 The goal is to deliver 2 novel phase 2 clinical trials to accelerate the development of new anti-tuberculosis drugs and regimens.\u00a0 The USTAN group plays a key role in Work package 7 to develop definitions for biomarkers to monitor treatment effectiveness.<\/p>\n
[\/et_pb_text][\/et_pb_column][\/et_pb_row][\/et_pb_section]<\/p>\n","protected":false},"excerpt":{"rendered":"
UNITE4TBSeven year \u20ac185 million project.\u00a0 Thirty partners from 13 countries to deliver an efficient global clinical trials network equipped to implement phase 2 trials that conform to the highest regulatory standards.\u00a0 The goal is to deliver 2 novel phase 2 clinical trials to accelerate the development of new anti-tuberculosis drugs and regimens.\u00a0 The USTAN group […]<\/p>\n","protected":false},"author":159,"featured_media":0,"parent":3571,"menu_order":0,"comment_status":"closed","ping_status":"closed","template":"","meta":{"_et_pb_use_builder":"on","_et_pb_old_content":"
Seven year \u20ac185 million project.\u00a0 Thirty partners from 13 countries to deliver an efficient global clinical trials network equipped to implement phase 2 trials that conform to the highest regulatory standards.\u00a0 The goal is to deliver 2 novel phase 2 clinical trials to accelerate the development of new anti-tuberculosis drugs and regimens.\u00a0 The UStAn<\/a> group plays a key role in Work package 7 to develop definitions for biomarkers to monitor treatment effectiveness.<\/p>","_et_gb_content_width":"","_monsterinsights_skip_tracking":false,"_monsterinsights_sitenote_active":false,"_monsterinsights_sitenote_note":"","_monsterinsights_sitenote_category":0,"footnotes":""},"class_list":["post-5990","page","type-page","status-publish","hentry"],"publishpress_future_action":{"enabled":false,"date":"2026-05-11 19:08:27","action":"change-status","newStatus":"draft","terms":[],"taxonomy":"","extraData":[]},"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/pages\/5990","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/pages"}],"about":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/types\/page"}],"author":[{"embeddable":true,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/users\/159"}],"replies":[{"embeddable":true,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/comments?post=5990"}],"version-history":[{"count":2,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/pages\/5990\/revisions"}],"predecessor-version":[{"id":7056,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/pages\/5990\/revisions\/7056"}],"up":[{"embeddable":true,"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/pages\/3571"}],"wp:attachment":[{"href":"https:\/\/medicine.st-andrews.ac.uk\/tbtrials\/wp-json\/wp\/v2\/media?parent=5990"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}